{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:43:55Z","timestamp":1793731435818,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","tipsro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Technical Innovations & Patient Support in Radiation Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.tipsro.2026.100399","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:19:55Z","timestamp":1776075595000},"page":"100399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Stereotactic body radiotherapy combined with immunotherapy: a systematic review focus on timing and toxicity profile"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5121-9338","authenticated-orcid":false,"given":"Carlo Gugliemo","family":"Cattaneo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7722-290X","authenticated-orcid":false,"given":"Giuditta","family":"Chiloiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Panza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4146-9572","authenticated-orcid":false,"given":"Matteo","family":"Galetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0122-9347","authenticated-orcid":false,"given":"Matteo","family":"Nardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Placidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5455-8737","authenticated-orcid":false,"given":"Maria Antonietta","family":"Gambacorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Boldrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tipsro.2026.100399_b0005","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5415\/apallergy.0000000000000146","article-title":"From tumor to tolerance: a comprehensive review of immune checkpoint inhibitors and immune-related adverse events","volume":"14","author":"Sutanto","year":"2024","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.tipsro.2026.100399_b0010","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: a paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.tipsro.2026.100399_b0015","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tipsro.2026.100399_b0020","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.3390\/cancers14184530","article-title":"The evolving interplay of SBRT and the immune system, along with future directions in the field","volume":"14","author":"Miljanic","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tipsro.2026.100399_b0025","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.tipsro.2026.100399_b0030","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","article-title":"Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade","volume":"23","author":"Dovedi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tipsro.2026.100399_b0035","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.tipsro.2026.100399_b0040","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti\u2013CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tipsro.2026.100399_b0045","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.tipsro.2026.100399_b0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijrobp.2019.02.046","article-title":"Immunomodulatory effects of stereotactic body radiation therapy: preclinical insights and clinical opportunities","volume":"110","author":"Marciscano","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.tipsro.2026.100399_b0055","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/S1470-2045(24)00656-9","article-title":"Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation","volume":"26","author":"Morris","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tipsro.2026.100399_b0060","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.tipsro.2026.100399_b0065","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a european society for radiotherapy and oncology and european organisation for research and treatment of cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tipsro.2026.100399_b0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A Phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study","volume":"17","author":"Bestvina","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.tipsro.2026.100399_b0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000492","article-title":"Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.tipsro.2026.100399_b0080","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cllc.2021.01.012","article-title":"A prospective trial evaluating the safety and systemic response from the concurrent use of radiation therapy with checkpoint inhibitor immunotherapy in metastatic non-small cell lung cancer","volume":"22","author":"Mattes","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.tipsro.2026.100399_b0085","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT Phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tipsro.2026.100399_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.tipsro.2026.100399_b0095","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1078-0432.CCR-16-1432","article-title":"Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T cells","volume":"23","author":"Tang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tipsro.2026.100399_b0100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jjco\/hyy171","article-title":"Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer","volume":"49","author":"Miyamoto","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.tipsro.2026.100399_b0105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13014-021-01905-3","article-title":"Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial","volume":"16","author":"Ni","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.tipsro.2026.100399_b0110","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1016\/j.cllc.2021.02.005","article-title":"The NIPRO study: an observational, retrospective, multicenter study on the safety of the radiotherapy and immunotherapy combination for advanced-stage NSCLC","volume":"22","author":"Perna","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.tipsro.2026.100399_b0115","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijrobp.2019.10.047","article-title":"A pilot study of atezolizumab plus hypofractionated image guided radiation therapy for the treatment of advanced non-small cell lung cancer","volume":"108","author":"Qin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.tipsro.2026.100399_b0120","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1158\/2326-6066.CIR-15-0156","article-title":"Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma","volume":"4","author":"Theurich","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.tipsro.2026.100399_b0125","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijrobp.2020.05.022","article-title":"Stereotactic radiation therapy combined with immunotherapy against metastatic melanoma: long-term results of a Phase 1 clinical trial","volume":"108","author":"Ratnayake","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.tipsro.2026.100399_b0130","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ijrobp.2017.11.029","article-title":"Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma","volume":"100","author":"Sundahl","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.tipsro.2026.100399_b0135","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1158\/2326-6066.CIR-18-0793","article-title":"Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses","volume":"7","author":"Welsh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.tipsro.2026.100399_b0140","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1214788","article-title":"Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma","volume":"5","author":"Liniker","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tipsro.2026.100399_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007279","article-title":"First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial","volume":"11","author":"De Caluwe","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.tipsro.2026.100399_b0150","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.91737","article-title":"Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: a pilot study","volume":"12","author":"Chen","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.tipsro.2026.100399_b0155","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.tipsro.2026.100399_b0160","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/cncr.32599","article-title":"A phase 2 clinical trial\u00a0assessing the\u00a0efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer","volume":"126","author":"Ho","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.tipsro.2026.100399_b0165","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2021.08.011","article-title":"Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the Phase 2 ICE-PAC clinical trial","volume":"81","author":"Kwan","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.tipsro.2026.100399_b0170","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/j.clgc.2019.12.009","article-title":"Real world experience with pembrolizumab in recurrent or advanced prostate cancer","volume":"18","author":"Higa","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.tipsro.2026.100399_b0175","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.tipsro.2026.100399_b0180","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-19-3624","article-title":"Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma","volume":"26","author":"Xie","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tipsro.2026.100399_b0185","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(22)00066-3","article-title":"Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Zhu","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tipsro.2026.100399_b0190","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized Phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tipsro.2026.100399_b0195","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2021.09.016","article-title":"Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. results of the phase II NIVES study","volume":"81","author":"Masini","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.tipsro.2026.100399_b0200","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-the RAPPORT trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.tipsro.2026.100399_b0205","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.tipsro.2026.100399_b0210","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3390\/biomedicines13092107","article-title":"Immunomodulatory effects of high-dose irradiation regimens in renal cell carcinoma: insights from an in vitro model with human peripheral blood mononuclear cell","volume":"13","author":"Meniai Merzouki","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.tipsro.2026.100399_b0215","doi-asserted-by":"crossref","first-page":"S468","DOI":"10.21037\/jtd.2018.01.130","article-title":"Combining radiation plus immunotherapy to improve systemic immune response","volume":"10","author":"Cushman","year":"2018","journal-title":"J Thorac Dis"},{"issue":"3","key":"10.1016\/j.tipsro.2026.100399_b0220","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ijrobp.2015.11.048","article-title":"Phase 1 trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma","volume":"94","author":"Brade","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Technical Innovations & Patient Support in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405632426000260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405632426000260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:23:40Z","timestamp":1784273020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405632426000260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"alternative-id":["S2405632426000260"],"URL":"https:\/\/doi.org\/10.1016\/j.tipsro.2026.100399","relation":{},"ISSN":["2405-6324"],"issn-type":[{"value":"2405-6324","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic body radiotherapy combined with immunotherapy: a systematic review focus on timing and toxicity profile","name":"articletitle","label":"Article Title"},{"value":"Technical Innovations & Patient Support in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tipsro.2026.100399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy & Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100399"}}